LONA
LeonaBio, Inc.
Overview
LeonaBio develops small-molecule therapeutics for treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
LeonaBio, Inc is a Healthcare company operating in Biotechnology with a $77.0M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-1.90—Rev— vs ——EODHD
- Q1 FY20262026-05-07EPS$-1.73 vs $-2.50+30.8%Rev$0 vs ——EODHD
- Q4 FY20252026-03-26EPS$-18.92 vs $-1.27-100.0%Rev$0 vs ——EODHD
- Q3 FY20252025-11-05EPS$-1.68 vs $-0.13-100.0%Rev$0 vs ——EODHD
- Q2 FY20252025-08-06EPS$-1.78 vs $-0.22-100.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-08EPS$-0.23 vs $-0.18-27.8%Rev$0 vs ——EODHD
- Q4 FY20242025-02-26EPS$-0.38 vs $-0.380.0%Rev$0 vs ——EODHD
- Q3 FY20242024-11-07EPS$-0.75 vs $-0.70-7.1%Rev$0 vs ——EODHD
- Q2 FY20242024-07-31EPS$-0.70 vs $-0.74+5.4%Rev— vs ——EODHD
- Q1 FY20242024-05-14EPS$-0.69 vs $-0.690.0%Rev— vs ——EODHD
- Q4 FY20232024-02-21EPS$-0.71 vs $-0.710.0%Rev— vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.87 vs $-0.870.0%Rev— vs ——EODHD
- Q2 FY20232023-08-10EPS$-0.78 vs $-0.780.0%Rev— vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.19 vs $-0.65+70.8%Rev— vs ——EODHD
- Q4 FY20222023-03-22EPS$-0.79 vs $-0.790.0%Rev— vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.53 vs $-0.530.0%Rev— vs ——EODHD
- Q2 FY20222022-08-14EPS$-0.65 vs $-0.650.0%Rev— vs ——EODHD
- Q1 FY20222022-05-11EPS$-0.56 vs $-0.560.0%Rev— vs ——EODHD
- Q4 FY20212022-03-23EPS$-0.44 vs $-0.440.0%Rev— vs ——EODHD
- Q3 FY20212021-11-09EPS$-0.42 vs $-0.420.0%Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-1.90 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-07 | $-1.73 | $-2.50 | +30.8% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-18.92 | $-1.27 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-1.68 | $-0.13 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-1.78 | $-0.22 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-08 | $-0.23 | $-0.18 | -27.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-26 | $-0.38 | $-0.38 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-07 | $-0.75 | $-0.70 | -7.1% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.70 | $-0.74 | +5.4% | — | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-0.69 | $-0.69 | 0.0% | — | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.71 | $-0.71 | 0.0% | — | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.87 | $-0.87 | 0.0% | — | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-0.78 | $-0.78 | 0.0% | — | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.19 | $-0.65 | +70.8% | — | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-0.79 | $-0.79 | 0.0% | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.53 | $-0.53 | 0.0% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.65 | $-0.65 | 0.0% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.56 | $-0.56 | 0.0% | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-0.44 | $-0.44 | 0.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.42 | $-0.42 | 0.0% | — | — | — | EODHD |
Source: EODHD. LONA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks LONA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 3 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2021 | $1.22 | $1.21 | +1.2% | +4.5% | +5.4% |
| Q4 FY2021 | $1.07 | $1.18 | -9.3% | -7.2% | -6.4% |
| Q3 FY2021 | $1.34 | $1.41 | -5.3% | -0.2% | -0.4% |
| Q2 FY2021 | $1.29 | $1.37 | -5.7% | +1.7% | -0.8% |
| Q1 FY2020 | $1.32 | $1.26 | +4.9% | +4.4% | +2.6% |
| Q4 FY2020 | $1.31 | $1.38 | -5.1% | +0.6% | +1.6% |
| Q3 FY2020 | $1.23 | $1.30 | -5.1% | +1.3% | +1.4% |
| Q2 FY2020 | $1.40 | $1.50 | -6.8% | +3.7% | +1.2% |
| Q1 FY2019 | $1.38 | $1.30 | +6.1% | -4.0% | -2.5% |
| Q4 FY2019 | $1.40 | $1.32 | +6.0% | -2.3% | -1.6% |
Guidance change history
Sample- Q1 FY2021Maintained2021-04-15
- Q4 FY2021Lowered2021-13-15
- Q3 FY2021Lowered2021-10-15
- Q2 FY2021Lowered2021-07-15
- Q1 FY2020Raised2020-04-15
- Q4 FY2020Lowered2020-13-15
- Q3 FY2020Lowered2020-10-15
- Q2 FY2020Lowered2020-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Mark James LittonCEO3 mono recorded callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • last guidance raise Q1 FY2021
- Robert RenningerCFO3 mono recorded callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2021
- Mark WorthingtonGENERAL COUNSEL and CCO3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last call held guidance Q1 FY2021
- Kevin ChurchCHIEF SCIENTIFIC OFFICER1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance cut Q2 FY2021
- Martin Javier SanCHIEF MEDICAL OFFICER1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance raise Q2 FY2021
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LONA.
$ curl https://api.spokenalpha.com/v1/companies/LONAFAQ
Frequently asked about LONA
Where can I find LeonaBio, Inc.'s (LONA) earnings call transcripts?
Spoken Alpha indexes LONA's earnings call transcripts at https://spokenalpha.com/companies/LONA. Each call links to attributed speakers and parsed analyst Q&A. LeonaBio, Inc.'s own investor relations page is at https://investors.leonabio.com/.
When was LeonaBio, Inc.'s most recent earnings call?
LeonaBio, Inc. (LONA) held its most recent earnings call on 2022-03-24, covering fiscal Q4 2021.
What sector is LONA in?
LeonaBio, Inc. (LONA) operates in the Healthcare sector (Biotechnology industry).